DB:EAJD

Stock Analysis Report

Executive Summary

ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom.


Snowflake Analysis

Imperfect balance sheet and overvalued.

Share Price & News

How has ValiRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EAJD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

EAJD

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-98.8%

EAJD

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: EAJD underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: EAJD underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

EAJDIndustryMarket
7 Day0%-2.3%-0.2%
30 Day0%-3.2%0.3%
90 Day-90.0%6.3%3.7%
1 Year-98.8%-98.8%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is ValiRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ValiRx undervalued compared to its fair value and its price relative to the market?

0.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EAJD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EAJD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EAJD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: EAJD is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EAJD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EAJD is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is ValiRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ValiRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ValiRx performed over the past 5 years?

-7.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EAJD is currently unprofitable.

Growing Profit Margin: EAJD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EAJD is unprofitable, and losses have increased over the past 5 years at a rate of -7.3% per year.

Accelerating Growth: Unable to compare EAJD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EAJD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: EAJD has a negative Return on Equity (-95.23%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ValiRx's financial position?


Financial Position Analysis

Short Term Liabilities: EAJD's short term assets (£962.6K) do not cover its short term liabilities (£1.0M).

Long Term Liabilities: EAJD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EAJD's debt to equity ratio (6.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if EAJD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: EAJD has a low level of unsold assets or inventory.

Debt Coverage by Assets: EAJD's debt is covered by short term assets (assets are 4.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EAJD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EAJD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is ValiRx's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EAJD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EAJD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EAJD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EAJD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EAJD's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.3yrs

Average board tenure


CEO

Satu Vainikka (52yo)

UK£213,572

Compensation

Dr. Satu Vainikka, Ph.D., MBA, serves as Chief Executive Officer at ValiRx plc. Dr. Vainikka is associated with ValiRx Finland Oy. She has been Director at ValiRx plc since October 2006. She serves as Dire ...


CEO Compensation Analysis

Compensation vs Market: Satu's total compensation ($USD274.97K) is below average for companies of similar size in the German market ($USD412.50K).

Compensation vs Earnings: Satu's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Satu Vainikka
Founding Director & CEO0yrsUK£213.57k0.13% £1.5k
James Desler
Founding Director & CFO13.8yrsUK£80.57k0.12% £1.5k
George Morris
Founding Director & COO13.3yrsUK£177.49k0.12% £1.4k
Kevin Alexander
Secretary & Independent Non-Executive Director13.3yrsUK£47.97k0.0068% £80.8
Seppo Mäkinen
Member of Advisory Board2.7yrsUK£10.68kno data
Andrew King
Member of Advisory Board2.7yrsno datano data
Alan Calvert
Member of Scientific Advisory Board0yrsno datano data
Ajay Agrawal
Member of Advisory Board2.7yrsno datano data
Richard Harbottle
Member of Scientific Advisory Board0yrsno datano data

13.3yrs

Average Tenure

63yo

Average Age

Experienced Board: EAJD's board of directors are seasoned and experienced ( 13.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 114.2%.


Top Shareholders

Company Information

ValiRx plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ValiRx plc
  • Ticker: EAJD
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£997.637k
  • Listing Market Cap: UK£1.190m
  • Shares outstanding: 1.53b
  • Website: https://www.valirx.com

Number of Employees


Location

  • ValiRx plc
  • Stonebridge House
  • Chelmsford Road
  • Hatfield
  • CM22 7BD
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VALAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2006
EAJDDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2006

Biography

ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company’s lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/21 00:04
End of Day Share Price2020/02/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.